AZNAstraZenecaRunning, no new patients
Assessment of Efficacy and Safety of Monalizumab Plus Cetuximab Compared to Placebo Plus Cetuximab in Recurrent or Metastatic Head and Neck Cancer
Squamous Cell Carcinoma of the Head and Neck
0Calmworry score, out of 100
No strong warning signs right now. The score counts warning signs; it is not a prediction.
Why this score
No warning signs right now. That's why the score is 0.
Score over time
- Stage
- Phase 3
- Patients
- 370 (final count)
- Started
- Oct 2, 2020
- Main results expected
- May 11, 2022
- Fully finished
- Sep 24, 2026
- Results posted
- Nov 18, 2023
What counts as success
The trial's main goal(s), called the “primary outcome.”
Overall Survival (OS) in Human Papillomavirus (HPV)-Unrelated Analysis Set
Measured over: Baseline (-28 to -1) through 17.5 months (maximum observed duration)
Changes Tremor has spotted
No changes since Tremor started watching this trial.
Show details (technical version)
Score inputs
- none
Raw record changes
- none yet
Trial ID NCT04590963 · record last updated 2026-09-09 · checked 2026-11-09 15:47 UTC